Quadrivalent Inactivated Influenza Vaccine (Inactivated Split Virion) (QIIV) 
FLUZONE® HIGH-DOSE QUADRIVALENT  Supplier: Sanofi Pasteur

INDICATIONS:
• Individuals 65 years of age and older living in long term care, assisted living facilities and First Nations communities.

The vaccine is not approved for use in those under 65 years of age.

DOSES AND SCHEDULE:
• 1 dose given as 0.7 mL IM.

ADMINISTRATION:
No additional requirements.

BOOSTER DOSES AND RE-IMMUNIZATION:
Annually.

SEROLOGICAL TESTING:
Serological testing is not recommended before or after immunization.

CONTRAINDICATIONS:
1. History of anaphylactic reaction to a previous dose of any type of influenza vaccine or to any component of FLUZONE® HIGH-DOSE QUADRIVALENT.
2. History of Guillain-Barré syndrome (GBS) within 8 weeks of receipt of a previous dose of influenza vaccine without another cause being identified.
3. Receipt of a CTLA-4 inhibitor (e.g., ipilimumab) alone or in combination with other checkpoint inhibitors for the treatment of cancer. Inactivated influenza vaccine should be given 4-6 weeks before starting treatment or 4-6 weeks after the last dose. For more specific details refer to the BC Cancer Influenza vaccine recommendations.

PRODUCT COMPONENTS:
Potential allergens: ovalbumin.
Other components: formaldehyde, sodium phosphate-buffered isotonic sodium chloride solution, octylphenol ethoxylate (Triton® X-100).

PRECAUTIONS:
Not applicable.

SPECIAL CONSIDERATIONS:
Egg allergic individuals (including those who have experienced anaphylaxis following egg ingestion) can be immunized with inactivated or live attenuated influenza vaccine in any setting attended by immunization service providers who are following standard vaccine administration practice. ^

^ See Safety Issues Applicable to Influenza Vaccines, 1. Egg Allergic Individuals.
Quadrivalent Inactivated Influenza Vaccine (Inactivated Split Virion) (QIIV) FLUZONE® HIGH-DOSE QUADRIVALENT Supplier: Sanofi Pasteur

ADVERSE EVENTS A:
Local: pain, redness, swelling, induration, bruising.
Systemic: myalgia, headache, malaise, shivering. Fewer than 1 in 20 people may develop oculo-respiratory syndrome (ORS). Symptoms include red eyes, a cough, and/or sore throat and/or hoarseness.

A These occur at similar frequencies among recipients of other influenza vaccines, are of short duration and rarely interfere with activities of daily living.